# US 2015/0105442 A1 · Nucleic Acid Molecule Capable of Inhibiting Expression of Periostin Gene, method for Inhibiting Expression of Periostin Gene, and Use of Said Nucleic Acid Molecule

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105442 A1
- Document ID: US20150105442A1
- Status: Published application
- Kind: A1
- Application number: 14/389,188
- Filed: 2013-03-29
- Published: 2015-04-16
- Earliest claimed: 2012-03-29
- Assignees: AQUA Therapeutics Co., Ltd.; Kyushu University, National University Corporation
- Applicants: Kyushu University National University Corporation; AQUA Therapeutics Co., Ltd.
- Inventors: Shigeo Yoshida; Tomohiro Hamasaki; Keijiro Ishikawa; Takayuki Mizutani; Tatsuro Ishibashi; Tadaaki Ohgi; Takahito Nakama
- Web page: https://patentgrep.com/patent/US20150105442A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/532: Closed or circular
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a novel molecule that inhibits the expression of the periostin gene. Also provided are methods of inhibiting the expression of the periostin gene or treating an eye disease using the same.

## Claims

### Claim 1

An expression inhibitory nucleic acid molecule comprising nucleotide (as1), (as2), or (as3): wherein,
the nucleotide (as1) has a base sequence represented by any one of SEQ ID NOs: 1 to 19;
the nucleotide (as2) has a base sequence obtained by deletion, substitution, and/or addition of one to several bases in the base sequence of the nucleotide (as1) and has a function of inhibiting expression of the periostin gene; and
the nucleotide (as3) has a base sequence with an identity of at least 90% to the base sequence of the nucleotide (as1) and has a function of inhibiting expression of the periostin gene.

### Claim 2 (depends on 1)

The expression inhibitory nucleic acid molecule according to claim 1, wherein
the expression inhibitory nucleic acid molecule is a single-stranded nucleic acid molecule,
the single-stranded nucleic acid molecule comprises, in sequence from a 5′ side to a 3′ side: a 5′ side region (Xc); an inner region (Z); and a 3′ side region (Yc),
the inner region (Z) is composed of an inner 5′ side region (X) and an inner 3′ side region (Y) that are linked to each other,
the 5′ side region (Xc) is complementary to the inner 5′ side region (X),
the 3′ side region (Yc) is complementary to the inner 3′ side region (Y), and
the inner region (Z) comprises the expression inhibitory sequence.

### Claim 3 (depends on 2)

The expression inhibitory nucleic acid molecule according to claim 2, further comprising:
a linker region (Lx) between the 5′ side region (Xc) and the inner 5′ side region (X); and
a linker region (Ly) between the 3′ side region (Yc) and the inner 3′ side region (Y),
wherein the 5′ side region (Xc) and the inner 5′ side region (X) are linked to each other via the linker region (Lx), and
the 3′ side region (Yc) and the inner 3′ side region (Y) are linked to each other via the linker region (Ly).

### Claim 4 (depends on 3)

The expression inhibitory nucleic acid molecule according to claim 3, wherein
the linker regions (Lx) and (Ly) each comprise a nucleotide residue.

### Claim 5 (depends on 3)

The expression inhibitory nucleic acid molecule according to claim 3, wherein the linker regions (Lx) and (Ly) each comprise a non-nucleotide residue.

### Claim 6 (depends on 5)

The expression inhibitory nucleic acid molecule according to claim 5, wherein the non-nucleotide residue comprises at least one of a pyrrolidine skeleton and a piperidine skeleton.

### Claim 7 (depends on 5)

The expression inhibitory nucleic acid molecule according to claim 5, wherein the linker regions (Lx) and (Ly) are each represented by the following formula (I):
where:
X1 and X2 are each independently H2, O, S, or NH;
Y2 and Y2 are each independently a single bond, CH2, NH, O, or S;
R3 is a hydrogen atom or substituent that is bound to C-3, C-4, C-5, or C-6 on a ring A;
L1 is an alkylene chain composed of n atoms, and a hydrogen atom on an alkylene carbon atom may or may not be substituted with OH, ORa, NH2, NHRa, NRaRb, SH, or SRa, or
L1 is a polyether chain obtained by substituting at least one carbon atom on the alkylene chain with an oxygen atom,
provided that: when Y2 is NH, O, or S, an atom bound to Y2 in L1 is carbon, an atom bound to OR1 in L1 is carbon, and oxygen atoms are not adjacent to each other;
L2 is an alkylene chain composed of m atoms, and a hydrogen atom on an alkylene carbon atom may or may not be substituted with OH, ORc, NH2, NHRc, NRcRd, SH, or SRc, or
L2 is a polyether chain obtained by substituting at least one carbon atom on the alkylene chain with an oxygen atom,
provided that: when Y2 is NH, O, or S, an atom bound to Y2 in L2 is carbon, an atom bound to OR2 in L2 is carbon, and oxygen atoms are not adjacent to each other;
Ra, Rb, Rc, and Rd are each independently a substituent or a protecting group;
l is 1 or 2;
m is an integer in the range from 0 to 30;
n is an integer in the range from 0 to 30;
on the ring A, one carbon atom other than C-2 may be substituted with nitrogen, oxygen, or sulfur,
the ring A may comprise a carbon-carbon double bond or a carbon-nitrogen double bond; and
the regions (Xc) and (X) are each linked to the linker region (Lx) via —OR1— or —OR2—, where R1 and R2 may or may not be present, and when they are present, Wand R2 are each independently a nucleotide residue or the structure of the formula (I).

### Claim 8 (depends on 2)

The expression inhibitory nucleic acid molecule according to claim 2, wherein
the number of bases (Z) in the inner region (Z), the number of bases (X) in the inner 5′ side region (X), the number of bases (Y) in the inner 3′ side region (Y), the number of bases (Xc) in the 5′ side region (Xc), and the number of bases (Yc) in the 3′ side region (Yc) satisfy conditions of Expressions (1) and (2) below:
Z=X+Y (1)
Z≧Xc+Yc (2).

### Claim 9 (depends on 8)

The expression inhibitory nucleic acid molecule according to claim 8, wherein the difference between the number of bases (X) in the inner 5′ side region (X) and the number of bases (Xc) in the 5′ side region (Xc), and the difference between the number of bases (Y) in the inner 3′ side region (Y) and the number of bases (Yc) in the 3′ side region (Yc) satisfy the following conditions:
(a) Conditions of Expressions (11) and (12) are satisfied;
X−Xc=1, 2, or 3 (11)
Y−Yc=0 (12)
(b) Conditions of Expressions (13) and (14) are satisfied;
X−Xc=0 (13)
Y−Yc=1, 2, or 3 (14)
(c) Conditions of Expressions (15) and (16) are satisfied;
X−Xc=1, 2, or 3 (15)
Y−Yc=1, 2, or 3 (16)
(d) Conditions of Expressions (17) and (18) are satisfied;
X−Xc=0 (17)
Y−Yc=0 (18).

### Claim 10 (depends on 1)

The expression inhibitory nucleic acid molecule according to claim 1, wherein
the expression inhibitory sequence has a length of 18- to 32-mer.

### Claim 11 (depends on 1)

The expression inhibitory nucleic acid molecule according to claim 1, wherein
the sequence of the expression inhibitory nucleic acid molecule is at least one base sequence selected from the group consisting of SEQ ID NOs: 83 to 97.

### Claim 12 (depends on 1)

The expression inhibitory nucleic acid molecule according to claim 1, wherein
the expression inhibitory sequence further comprises an overhang sequence, and
the overhang sequence is added to the 3′ end of the nucleotide.

### Claim 13 (depends on 1)

The expression inhibitory nucleic acid molecule according to claim 1, wherein
the expression inhibitory sequence is a nucleotide that has a base sequence represented by any one of SEQ ID NOs: 20 to 38 (where n is a positive integer) comprising the nucleotide (as1).

### Claim 14 (depends on 1)

The expression inhibitory nucleic acid molecule according to claim 1, wherein
the expression inhibitory sequence has a length of 18- to 32-mer.

### Claim 15 (depends on 1)

The expression inhibitory nucleic acid molecule according to claim 1, further comprising a complementary sequence that anneals to the expression inhibitory sequence,
wherein the complementary sequence comprises a nucleotide that is complementary to the nucleotide (as1), (as2), or (as3) in the expression inhibitory sequence.

### Claim 16 (depends on 15)

The expression inhibitory nucleic acid molecule according to claim 15, wherein
the nucleotide in the complementary sequence is the following nucleotide (s1), (s2), or (s3):
(s1) a nucleotide that has a base sequence complementary to the base sequence of the nucleotide (as1);
(s2) a nucleotide that has a base sequence complementary to the base sequence of the nucleotide (as2); and
(s3) a nucleotide that has a base sequence complementary to the base sequence of the nucleotide (as3).

### Claim 17 (depends on 16)

The expression inhibitory nucleic acid molecule according to claim 16, wherein
the nucleotide (s1) has a base sequence represented by any one of SEQ ID NOs: 39 to 57.

### Claim 18 (depends on 15)

The expression inhibitory nucleic acid molecule according to claim 15, wherein
the complementary sequence further comprises an overhang sequence, and
the overhang sequence is added to the 5′ end of the nucleotide.

### Claim 19 (depends on 15)

The expression inhibitory nucleic acid molecule according to claim 15, wherein
the complementary sequence is a nucleotide that has a base sequence represented by any one of SEQ ID NOs: 58 to 76 (where n is a positive integer) comprising the nucleotide (s1).

### Claim 20 (depends on 12)

The expression inhibitory nucleic acid molecule according to claim 12, wherein
the overhang sequence has a length of 1- to 3-mer.

### Claim 21 (depends on 12)

The expression inhibitory nucleic acid molecule according to claim 12, wherein
the expression inhibitory nucleic acid molecule is a double-stranded nucleic acid molecule composed of two single strands, and an antisense strand thereof comprises the expression inhibitory sequence and a sense strand thereof comprises the complementary sequence.

### Claim 22 (depends on 1)

A composition comprising:
the expression inhibitory nucleic acid molecule according to claim 1.

### Claim at position 23

23-25. (canceled)

### Claim 26 (depends on 1)

A method of inhibiting expression of the periostin gene, wherein
administering the expression inhibitory nucleic acid molecule according to claim 1 to a cell, a tissue, or an organ.

### Claim 27

(canceled)

### Claim 28 (depends on 26)

The method according to claim 26, wherein
the expression inhibitory nucleic acid molecule is administered in vivo or in vitro.

### Claim 29 (depends on 1)

A method of treating an eye disease, the method comprising the step of:
administering an effective amount of the expression inhibitory nucleic acid molecule according to claim 1 to a patient in need thereof.

### Claim 30 (depends on 29)

The treatment method according to claim 29, wherein
the eye disease is at least one selected from the group consisting of retinopathy, macular degeneration, pterygium, conjunctivitis, intraocular neovascularization, and fibrous scar in the eye.

### Claim 31 (depends on 30)

The treatment method according to claim 30, wherein
the retinopathy is proliferative diabetic retinopathy or proliferative vitreoretinopathy.

### Claim at position 30

32-34. (canceled)
